Logo Logo
Hilfe
Hilfe
Switch Language to English

Ornello, Raffaele; Baraldi, Carlo; Ahmed, Fayyaz; Negro, Andrea; Miscio, Anna Maria; Santoro, Antonio; Alpuente, Alicia; Russo, Antonio; Silvestro, Marcello; Cevoli, Sabina; Brunelli, Nicoletta; Vernieri, Fabrizio; Grazzi, Licia; Pani, Luca; Andreou, Anna; Lambru, Giorgio; Frattale, Ilaria; Kamm, Katharina; Ruscheweyh, Ruth; Russo, Marco; Torelli, Paola; Filatova, Elena; Latysheva, Nina; Gryglas-Dworak, Anna; Straburzynski, Marcin; Butera, Calogera; Colombo, Bruno; Filippi, Massimo; Pozo-Rosich, Patricia; Martelletti, Paolo; Guerzoni, Simona und Sacco, Simona (2022): Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors. In: International Journal of Environmental Research and Public Health, Bd. 19, Nr. 17, 10975

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

The identification of patients who can benefit the most from the available preventive treatments is important in chronic migraine. We explored the rate of excellent responders to onabotulinumtoxinA in a multicenter European study and explored the predictors of such response, according to different definitions. A pooled analysis on chronic migraineurs treated with onabotulinumtoxinA and followed-up for, at least, 9 months was performed. Excellent responders were defined either as patients with a >= 75% decrease in monthly headache days (percent-based excellent responders) or as patients with <4 monthly headache days (frequency-based excellent responders). The characteristics of excellent responders at the baseline were compared with the ones of patients with a <30% decrease in monthly headache days. Percent-based excellent responders represented about 10% of the sample, whilst frequency-based excellent responders were about 5% of the sample. Compared with non-responders, percent-based excellent responders had a higher prevalence of medication overuse and a higher excellent response rate even after the 1st and the 2nd injection. Females were less like to be frequency-based excellent responders. Chronic migraine sufferers without medication overuse and of female sex may find fewer benefits with onabotulinumtoxinA. Additionally, the excellent response status is identifiable after the first cycle.

Dokument bearbeiten Dokument bearbeiten